meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
mCRC - (neo)adjuvant (NA)
mCRC - 1st line (L1)
2
mCRC - 2nd line (L2)
3
endometrial cancer
10
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
avelumab based treatment
avelumab plus SoC
dostarlimab based treatment
dostarlimab plus soC
durvalumab based treatment
durvalumab plus olaparib plus SoC
durvalumab plus SoC
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus lenvatinib
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
poly ADP-ribose polymerase (PARP) inhibitor
niraparib
talazoparib
VEGF(R) inhibitor
lenvatinib
lenvatinib in association
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs durvalumab based treatment
vs durvalumab alone
vs non active control
vs no additional treatment
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
table
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
click on circles to display study description...
powered by
vis.js Network